Trial record 1 of 1 for:    CP20-0903
Previous Study | Return to List | Next Study

Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01234402
Recruitment Status : Completed
First Posted : November 4, 2010
Last Update Posted : October 2, 2017
Information provided by (Responsible Party):
Eli Lilly and Company

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : October 2013
  Actual Study Completion Date : July 2017
  Certification/Extension First Submitted : September 29, 2014